Member Exclusive

FDA releases industry guidelines for epidermolysis bullosa therapies

The FDA has released new guidelines aiming to assist industry production of drug therapies for the prevention and treatment of epidermolysis bullosa (EB) cutaneous manifestations.

Go to the profile of RegMedNet
Jul 25, 2019

Please sign in or register for FREE

No comments yet.